Literature DB >> 2878881

Molecular basis for the pathological actions of Clostridium perfringens iota toxin.

L L Simpson, B G Stiles, H H Zepeda, T D Wilkins.   

Abstract

Clostridium perfringens type E iota toxin is composed of two separate and independent polypeptide chains that act synergistically in mouse lethal assays. The light chain is an enzyme that mono(ADP-ribosyl)ates certain amino acids. The enzyme displays substantial activity when homopoly-L-arginine is used as a substrate, but it shows little activity when polyasparagine, polylysine or polyglutamic acid are used. In keeping with the properties of an ADP-ribosylating enzyme, the toxin possesses the following characteristics. It produces incorporation of radioactivity into polyarginine when adenine-labeled NAD is used, but radioactivity is not incorporated when nicotinamide-labeled NAD is used. Irrespective of labeling, enzymatic activity is accompanied by the release of free nicotinamide. After incorporation of ADP-ribose groups into polyarginine, enzymatic and chemical techniques can be used to release the incorporated material. Snake venom phosphodiesterase releases mainly AMP; hydroxylamine releases AMP and ADP-ribose. The heavy chain of iota toxin has little or no enzyme activity, and it does not substantially affect the enzyme activity of the light chain. The heavy chain may be a binding component that directs the toxin to vulnerable cells. The data suggest that iota toxin is a representative of a novel class of ADP-ribosylating toxins.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2878881      PMCID: PMC260288          DOI: 10.1128/iai.55.1.118-122.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Activation of adenylate cyclase by heat-labile Escherichia coli enterotoxin. Evidence for ADP-ribosyltransferase activity similar to that of choleragen.

Authors:  J Moss; S H Richardson
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

Review 2.  Clostridium perfringens toxins (type A, B, C, D, E).

Authors:  J L McDonel
Journal:  Pharmacol Ther       Date:  1980       Impact factor: 12.310

3.  Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein.

Authors:  T Katada; M Ui
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

4.  Crystallization and properties of staphylococcal leukocidin.

Authors:  M Noda; T Hirayama; I Kato; F Matsuda
Journal:  Biochim Biophys Acta       Date:  1980-11-17

5.  Purification and characterization of two components of botulinum C2 toxin.

Authors:  I Ohishi; M Iwasaki; G Sakaguchi
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

6.  Evidence that botulinum C2 toxin has two dissimilar components.

Authors:  M Iwasaki; I Ohishi; G Sakaguchi
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

Review 7.  Anthrax toxin.

Authors:  J Stephen
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

8.  Purification of cholera toxin and its subunits: new methods of preparation and the use of hypertoxinogenic mutants.

Authors:  J J Mekalanos; R J Collier; W R Romig
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

9.  The susceptibility of the mallard duck (Anas platyrhynchos) to Clostridium botulinum C2 toxin.

Authors:  W I Jensen; R M Duncan
Journal:  Jpn J Med Sci Biol       Date:  1980-04

Review 10.  Current state of the art in the HPLC analyses of free nucleotides, nucleosides, and bases in biological fluids.

Authors:  P R Brown; A M Krstulovic; R A Hartwick
Journal:  Adv Chromatogr       Date:  1980
View more
  34 in total

1.  Clostridium perfringens iota-toxin: mapping of receptor binding and Ia docking domains on Ib.

Authors:  J C Marvaud; T Smith; M L Hale; M R Popoff; L A Smith; B G Stiles
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Characterization of the enzymatic component of Clostridium perfringens iota-toxin.

Authors:  M Nagahama; Y Sakaguchi; K Kobayashi; S Ochi; J Sakurai
Journal:  J Bacteriol       Date:  2000-04       Impact factor: 3.490

3.  The C terminus of component C2II of Clostridium botulinum C2 toxin is essential for receptor binding.

Authors:  D Blöcker; H Barth; E Maier; R Benz; J T Barbieri; K Aktories
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

4.  Binding component of Clostridium perfringens iota-toxin induces endocytosis in Vero cells.

Authors:  Masahiro Nagahama; Koichi Nagayasu; Keiko Kobayashi; Jun Sakurai
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

Review 5.  Clostridial ADP-ribosyltransferases--modification of low molecular weight GTP-binding proteins and of actin by clostridial toxins.

Authors:  K Aktories
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

Review 6.  Inhibiting bacterial toxins by channel blockage.

Authors:  Sergey M Bezrukov; Ekaterina M Nestorovich
Journal:  Pathog Dis       Date:  2015-12-09       Impact factor: 3.166

7.  Production by Clostridium spiroforme of an iotalike toxin that possesses mono(ADP-ribosyl)transferase activity: identification of a novel class of ADP-ribosyltransferases.

Authors:  L L Simpson; B G Stiles; H Zepeda; T D Wilkins
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

Review 8.  Toxigenic clostridia.

Authors:  C L Hatheway
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

Review 9.  Novel bacterial ADP-ribosylating toxins: structure and function.

Authors:  Nathan C Simon; Klaus Aktories; Joseph T Barbieri
Journal:  Nat Rev Microbiol       Date:  2014-07-14       Impact factor: 60.633

10.  ADP-ribosylation of Drosophila indirect-flight-muscle actin and arthrin by Clostridium botulinum C2 toxin and Clostridium perfringens iota toxin.

Authors:  I Just; E S Hennessey; D R Drummond; K Aktories; J C Sparrow
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.